Skip to main content

Table 3 Comparison of treatment-related adverse events between the modified XELOX and standard XELOX groups

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Adverse events standard XELOX
(n = 126, %)
modified XELOX
(n = 84, %)
P value
Neurotoxicity
 Total 96 (76.2) 33 (39.3) < 0.001
  Grade 1 61 (48.4) 20 (23.8) < 0.001
  Grade 2 31 (24.6) 11 (13.1) 0.041
  Grade 3–4 4 (3.2) 2 (2.4) 0.311
Leucopenia
 Total 88 (69.8) 45 (53.6) 0.017
  Grade 1 56 (44.4) 29 (34.5) 0.196
  Grade 2 22 (17.5) 10 (11.9) 0.329
  Grade 3–4 10 (7.9) 6 (7.1) 0.832
Thrombocytopenia
 Total 75 (59.5) 32 (38.1) 0.011
  Grade 1 45 (35.7) 17 (20.2) 0.016
  Grade 2 26 (20.6) 12 (14.3) 0.242
  Grade 3–4 4 (3.2) 3 (3.6) 0.592
Nausea/vomiting
 Total 46 (36.5) 26 (31.0) 0.861
  Grade 1 27 (21.4) 13 (15.5) 0.221
  Grade 2 18 (14.3) 10 (11.9) 0.683
  Grade 3–4 1 (0.8) 3 (3.6) 0.149
Diarrhea
 Total 17 (13.5) 11 (13.1) 0.934
  Grade 1 9 (7.1) 7 (8.3) 0.794
  Grade 2 5 (4.0) 3 (3.6) 0.883
  Grade 3–4 3 (2.4) 1 (1.2) 0.536
Hand-foot syndrome
 Total 50 (39.7) 23 (27.4) 0.067
  Grade 1 32 (25.4) 15 (17.9) 0.238
  Grade 2 13 (10.3) 5 (6.0) 0.128
  Grade 3–4 5 (4.0) 3 (3.6) 0.251
Hepatic disorder
 Total 46 (36.5) 22 (26.2) 0.134
  Grade 1 34 (27.0) 17 (20.2) 0.325
  Grade 2 10 (7.9) 4 (4.8) 0.414
  Grade 3–4 2 (1.6) 1 (1.2) 0.817
  1. XELOX oxaliplatin and capecitabine regimen
  2. The listed grades of peripheral sensory neurotoxicity represent the maximal levels at any time